Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APHD-012 in Pre-diabetes with Pathological OGTT
NCT05803772Phase 2Completed
- Sponsor
- Aphaia Pharma
- Start
- Mar 2023
- Primary completion
- Feb 2024
- Modality
- Small Molecules, Device-based Delivery
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of APHD-012 in prediabetes and impaired glucose tolerance (IGT) (2 arms), sponsored by Aphaia Pharma. Primary endpoint: Area Under the Curve from Time 0 to 2 Hours values of Oral Glucose Tolerance Test. Started Mar 2023; status: completed.
02
Drugs
APHD-012
03
Conditions
prediabetesimpaired glucose tolerance (IGT)
Beyond the preview
Go deeper on NCT05803772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05803772.